Vitamin D and Multiple Sclerosis

Experimental Biology and Medicine

Volumn 216, Issue 1, 1997, Pages 21-27

  Hayes, Colleen E ^a   Cantorna, Margherita T ^a   DeLuca, Hector F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; CONTROLLED STUDY; DEMYELINATING DISEASE; DIETARY INTAKE; IMMUNOREGULATION; MOUSE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; REVIEW; ULTRAVIOLET RADIATION; VITAMIN INTAKE;

ANIMALS; BRAIN; CALCITRIOL; CHOLECALCIFEROL; DIET; HUMANS; MICE; MULTIPLE SCLEROSIS; SUNLIGHT; ULTRAVIOLET RAYS;

ANIMALIA;

EID: 0030928680     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-216-44153a     Document Type: Article

References (65)

1. Steinman L. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 85:299-302, 1996.
2. Ebers GC, Sadovnick AD. The role of genetic factors in multiple sclerosis susceptibility. J Neuroimmunol 54:1-17, 1994.
3. Ebers GC, Bulman DE, Sadovnick AD, Paty DW, Warren S, Hader W, Murray TJ, Seland TP, Duquette P, Gray T, Nelson R, Nicolle M, Brunei D. A population-based twin study in multiple sclerosis. N Engl J Med 315:1638-1642, 1986.
4. Haines JL, Ter-Minassian M, Bazyk A, Gusella JF, Kim DJ, Terwedow H, Pericak-Vance MA, Rimmler JB, Haynes CS, Roses AD, Lee A, Shaner B, Menold M, Seboun E, Fitoussi RP, Gartioux C, Reyes C, Ribierre F, Gyapay G, Weissenbach J, Hauser SL, Goodkin DE, Lincoln R, Usuku K, Garcia-Moreno A, Gatto N, Young S, Oksenberg JR. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. The Multiple Sclerosis Genetics Groups. Nat Genet 13:469-471, 1996.
5. Sawcer S, Jones HB, Feakes R, Gray J, Smaldon N, Chataway J, Robertson N, Clayton D, Goodfellow PN, Compston A. A genome screen in multiple sclerosis reveals susceptibility loci on chromosomes 6p21 and 17q22. Nat Genet 13:464-468, 1996.
6. Ebers GC, Kukay K, Bulman DE, Sadovnick AD, Rice G, Andersen C, Armstrong H, Cousin K, Bell RB, Hader W, Paty DW, Hashimoto S, Ager J, Duquette P, Warren S, Gray T, O'Connor P, Nath A, Auty A, Metz L, Francis G, Paulseth JE, Murray TJ, Pryse-Phillips W, Nelson R, Freedman M, Brunei D, Bouchard J-P, Hinds D, Ritsch N. A full genome search in multiple sclerosis. Nat Genet 13:472-476, 1996.
7. Miller SD, Karpus WJ. The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases. Immunol Today 15:356-361, 1994.
8. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 6:382-427, 1993.
9. Brocke S, Veromaa T, Weissman I, Gijbels K, Steinman L. Infection and multiple sclerosis: A possible role for superantigens? Trends Microbiol 2:250-254, 1994.
10. Wucherpfennig KW, Strominger JL. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: A mechanism for MHC-linked susceptibility to human autoimmune diseases. J Exp Med 181:1597-1601, 1995.
11. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1:1313-1315, 1985.
12. Anderson O, Lygner P-E. Bergström T, Andersson M, Vahlne A. Viral infections trigger multiple sclerosis relapses: A prospective seroepidemiological study. J Neural 240:417-422, 1993.
13. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 36:S25-S28, 1994.
14. Johnson RT, Griffin DE, Hirsch RL, Wolinsky JS, Roedenbeck S, de Soriano IL, Vaisberg A. Measles encephalomyelitis - Clinical and immunologic studies. N Engl J Med 310:137-141, 1984.
15. Goldberg P. Multiple sclerosis: Vitamin D and calcium as environmental determinants of prevalence (a viewpoint). Part 1: Sunlight, dietary factors and epidemiology. Int J Environ Studies 6:19-27, 1974.
16. Goldberg P. Multiple sclerosis: Vitamin D and calcium as environmental determinants of prevalence (a viewpoint). Part 2: Biochemical and genetic factors. Int J Environ Studies 6:19-27, 1974.
17. Acheson ED. The epidemiology of multiple sclerosis. In: McAlpine D, Lumsden CE, Acheson ED, Eds. Multiple Sclerosis: A Reappraisal. 2nd Edition. Baltimore: Williams and Wilkins, pp3-80, 1972.
18. Alter M, Loewenson R, Harshe M. The geographic distribution of multiple sclerosis: An examination of mathematical models. J Chron Dis 26:755-767, 1973.
19. Kurtzke JF. Geography in multiple sclerosis. J Neurol 215:1-26, 1977.
20. Davenport CB. Multiple sclerosis from the standpoint of geographic distribution and race. Arch Neurol Psychial 8:51-58, 1922.
21. Limburg CC. Geographic distribution of multiple sclerosis and its estimated prevalence in the US. Res Publ Assoc Nerv Ment Dis 28:15-24, 1950.
22. Kurland LT. The frequency and geographic distribution of multiple sclerosis as indicated by mortality statistics and morbidity surveys in the United States and Canada. Am J Hyg 55:457-476, 1952.
23. Ulett G. Geographic distribution of multiple sclerosis. Dis Nerv Syst 9:342, 1948.
24. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Psychiat (Scand) 35(Suppl 147): 132-147, 1960.
25. Norman JE Jr., Kurtzke JF, Beebe GW. Epidemiology of multiple sclerosis in U.S. veterans: 2. Latitude, climate, and the risk of multiple sclerosis. J Chron Dis 36:551-559, 1983.
26. Acheson ED. Epidemiology of multiple sclerosis. Br Med Bull 33:9-14, 1977.
27. Dean G. Annual incidence, prevalence and mortality of multiple sclerosis in white South African-born and in white immigrants to South Africa. Br Med J 2:724-730, 1967.
28. Kurtzke JF, Dean G, Botha DPJ. A method for estimating the age at immigration of white immigrants to South Africa with an example of MS importance. S Afr Med J 44:663-669, 1970.
29. Kurtzke JF. On the fine structure of the distribution of multiple sclerosis. Acta Neurol Scand 43:257-282, 1967.
30. Geiger R. The Climate Near the Ground. Cambridge, MA: Harvard University Press, pp 442-446, 1965.
31. Presthus J. Report on the multiple sclerosis investigations in West Norway. Acta Psychiatr Neurol Scand 35(Suppl 147):88-92, 1960.
32. Westlund K. Distribution and mortality time trend of multiple sclerosis and some other diseases of Norway. Acta Neurol Scand 46:455-483, 1970.
33. Goldberg P, Fleming MC, Picard EM. Multiple sclerosis: Decreased relapse rate through dietary supplementation with calcium, magnesium, and vitamin D. Med Hypotheses 21:193-200, 1986.
34. Bates C, Cartlidge NEF, French JM, Jackson HJ, Nightenhale S, Shaw DA, Smith S, Woo E, Hawkins SA, Miller JH, Belin J, Conroy DM, Gill SK, Sidey M, Smith AD, Thompson RHS, Zilkha K, Gale M, Sinclair HM. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 52:18-22, 1989.
35. Newmark HL. Vitamin D adequacy: A possible relationship to breast cancer. In: Weisburger EK, Ed. Diet and Breast Cancer. New York: Plenum Press, pp 109-114, 1994.
36. DeLuca HF. Vitamin D: 1993. Nutrition Today 28:6-11, 1993.
37. Velluz L, Amiard G. Chimie organique-equilibre de reaction entre precalciferol et calciferol. Comput Rend 228:853-855, 1949.
38. Holick MF. The intimate relationship between the sun, skin and vitamin D: A new perspective. Bone 7:66-69, 1990.
39. Holick MF. Photosynthesis of vitamin D in the skin: Effect of environmental and life-style variables. Fed Proc 46:1876-1881, 1987.
40. 3 photosynthesis in man: Skin pigment is not an essential regulator. Science 211:590-593, 1981.
41. Clemens TL, Henderson SL, Adams JS, Holick MF. Increased skin pigment reduces the capacity of skin to synthesize vitamin D3. Lancet 9:75-76, 1982.
42. Holick MF. 1,25-Dihydroxyvitamin D, and the skin: A unique application for the treatment of psoriasis. Proc Soc Exp Biol Med 191:246-257, 1989.
43. 3: A unique photoendocrine system. J Invest Dermatol 76:51-58, 1981.
44. Holick MF. Photobiology, metabolism, and clinical aspects of vitamin D. In: Fotherby K. Pal SB, Eds. Hormones in Normal and Abnormal Human Tissues. Berlin: Walder de Gruyter, Vol. 2:pp 223-250, 1981.
45. DeLuca HF. Vitamin D: The vitamin and the hormone. Fed Proc 33:2211-2219, 1974.
46. Clemens TL, Adams JA, Nolan JM, Holick MF. Measurement of circulating vitamin D in man. Clin Chim Acta 121:301-308, 1982.
47. Boyle IT, Miravet L, Gray RW, Holick MF, DeLuca HF. The response of intestinal calcium transport to 25-hydroxy and 1,25-dihydroxy vitamin D in nephrectomized rats. Endocrinology 90:605-608, 1972.
48. Holick MF, Garabedian M, DeLuca HF. 5,6-Trans-25-hydroxy-cholecalciferol: Vitamin D analog effective on intestine of anephric rats. Science 176:1247-1248, 1972.
49. DeLuca HF. The vitamin D story: A collaborative effort of basic science and clinical medicine. FASEB J 2:224-236, 1988.
50. Garabedian M, Holick MF, DeLuca HF, Boyle IT. Control of 25-hydroxycholecalciferol metabolism by the parathyroid glands. Proc Natl Acad Sci U S A 69:1273-1676, 1972.
51. DeLuca HF, Schnoes HK. Vitamin D: Recent advances. Annu Rev Biochem 52:411-439, 1983.
52. Ross TK, Darwish HM, DeLuca HF. Molecular biology of vitamin D action. In: Litwck G, Ed. Vitamins and Hormones. San Diego: Academic Press, Vol 49:pp 281-326, 1994.
53. 3 receptors: Structure and function in transcription. Annu Rev Nutr 11:189-216, 1991.
54. 3 in human peripheral blood mononuclear cells: Presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 57: 1308-1311, 1983.
55. 3 receptor distribution and effects in subpopulations of normal human T lymphocytes. J Clin Endocrinol Metab 68:774-777, 1989.
56. 3: a novel immunoregulatory hormone. Science 224:1438-1440, 1984.
57. Yang S, Smith C, Prahl JM, DeLuca HF. Vitamin D deficiency suppresses cell-mediated immunity in vivo. Arch Biochem Biophys 303:98-106, 1993.
58. 2 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo. Biochim Biophys Acta 1158:279-286, 1993.
59. 3 and the immune system. Mol Cell Endocrinol 43:113-122, 1985.
60. Rigby WFC. The immunobiology of vitamin D. Immunol Today 9:54-57, 1988.
61. 3. J Cell Biochem 49:26-31, 1992.
62. 3 suppresses the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 87:1103-1107, 1991.
63. 3. J Neuroimmunol 61:151-160, 1995.
64. 3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 93:7861-7864, 1996.
65. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44:1687-1692, 1994.